7888 Share Price Performance
NT$0
-47.15 (-100.00%)
Price NT$0
Share Pricen/a
No recently updated narratives available.
Libo Pharma Corp., a clinical-stage biopharmaceutical company, engage in novel therapeutics development in the field of oncology and hematology. The company offers LIB-101, an interleukin-12 (IL-12) cytokine immunotherapy for innate immunity, adaptive immunity, and hematopoiesis. Libo Pharma Corp. was founded in 2017 and is based in Taipei, Taiwan.